Connect with us

International

3 Penny Stocks To Buy For Under $4 On Robinhood Right Now

Are these under $4 penny stocks on Robinhood worth it or not?
The post 3 Penny Stocks To Buy For Under $4 On Robinhood Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Published

3 years ago

on

Best Penny Stocks on Robinhood to Watch For Under $4 

Finding penny stocks on Robinhood is a great way to stay ahead in the stock market. While many investors believe that penny stocks are only traded on OTC markets, but it is actually quite the opposite. In reality, a penny stock is any security trading under $5 per share. And because of this, there are hundreds of options to choose from. 

But keep in mind that just because there are penny stocks for under $5 or even $4, does not mean that they are worth buying. And often, the risk with penny stocks can be high simply due to their low price. However, with the right research on hand, investors can decide based on their portfolio style and investing strategy, if penny stocks are worth it. 

Are Penny Stocks on Robinhood Worth It?

In the past few years, Robinhood has become the preferred trading platform for millions of investors. As a result, billions of dollars in new capital have flooded into the stock market. This has increased volume, and subsequently, market volatility. But, volatility is often a desired factor among penny stocks traders. 

[Read More] 10 Penny Stocks To Buy According To Top Wall Street Analysts In 2021

Investors should understand that this can result in either quick profits or even quicker losses. The best way to avoid this is by having a thorough understanding of what makes a specific penny stock or industry move. So, considering all of this, let’s take a look at three penny stocks to watch for under $4 on Robinhood. 

3 Penny Stocks on Robinhood For Your Under $4 Watchlist

  1. BIOLASE Inc. (NASDAQ: BIOL) 
  2. Atossa Therapeutics Inc. (NASDAQ: ATOS) 
  3. Kaixin Auto Holdings (NASDAQ: KXIN)

BIOLASE Inc. (NASDAQ: BIOL)

BIOLASE is a biotech company that creates laser systems for dental practitioners and their patients. The company is involved in the development, manufacturing, marketing, and sale of these laser systems. These systems allow dental specialists to perform cosmetic, surgical, and restorative procedures.

While the products that BIOLASE produces may take some time to see heightened adoption, there’s no doubting the potential that they have. In the medical industry, there is always room for improvement, and this is especially true when we consider standard procedures. On August 16th, BIOLASE announced that it has expanded its core capabilities by appointing 3 new board members that have significant dental experience.

“As we embark on an aggressive growth strategy, I am pleased to welcome the new Board members as their extensive experience in dental practice, translational and clinical research, and dental education will be extremely helpful as we continue to execute on the BIOLASE business plan.”

Chairman of the Board of BIOLASE, Jonathan T. Lord

With these new board members, the company may be able to have an easier time commercializing its products. In other recent news, the company just reported its second-quarter results. The company’s net revenue increased by 211% year over year to $9.1 million. Its net revenue was also 6% higher than its pre-pandemic revenues last year. BIOLASE laser system sales went up 424% year over year as well.

These numbers are very solid and show that BIOLASE is growing substantially right now. In the past month, shares of BIOL stock have increased by over 17% and YTD that number more than doubles to 39%. Keeping all of this in mind, will BIOL make your penny stocks watchlist?

Atossa Therapeutics Inc. (NASDAQ: ATOS)

In the biotech industry, it all comes down to which company is making the most breakthroughs. Additionally, investors like to find biotech stocks that have a correlation to current events. In line with this, Atossa Therapeutics Inc. is a biotech company that discovers and develops medicines based on oncology and infectious diseases.

One of its main programs is Endoxifen which is an active metabolite of tamoxifen. Endoxifen is in Phase II clinical trials to treat and prevent breast cancer at the moment. Additionally, Atossa has clinical trials in motion for treating COVID-19 patients.

On August 13th, the company announced its second-quarter financial results and a corporate update. In the results, Atossa stated that it ended the quarter with cash on hand of around $142 million. While it didn’t report any consistent revenue stream, this makes sense given that it is not in the commercialization stage with any of its products. However, it does have several with potentially promising futures.

[Read More] 5 Penny Stocks Analysts Say To Buy With Targets Up To 300%

Additionally, the company released final data from its Phase 2 Endoxifen clinical trial, which seemed positive. Atossa also received authorization from Swedish regulators to start a Phase 2 clinical study of Endoxifem to reduce mammographic breast density.

“We continue to experience encouraging progress in our MBD and COVID-19 programs, with new regulatory approvals being granted in Sweden for a Phase 2 trial in MBD and authorization in Australia to commence a Phase 2 study of AT-H201 for respiratory illness associated with COVID-19.”

President and CEO of Atossa, Dr. Steven Quay

Because of its relevance to Covid, the company has seen a high amount of attention in the past few months. YTD, shares of ATOS stock are up by around 243%, which is quite substantial. Considering this, will it be on your list of penny stocks to watch?

Penny_Stocks_to_Watch_Atossa_Therapeutics_Inc_ATOS_Stock_Chart

Kaixin Auto Holdings (NASDAQ: KXIN)

Kaixin Auto Holdings is a company that participates in the used car market in China. Specifically, it operates 14 used car dealerships across mainland China, which offers it quite a broad reach. It also provides financing channels to its customers through its partnerships with financial institutions. In addition to this, Kaixin provides insurance, extended warranties, and after-sales services to its customers.

On August 6th, the company announced that it will enter the market for new energy vehicles. The company will quickly start EV R&D, production, and marketing for the future of these products. A few days later, the company announced that it will start with the smaller size electric vehicle market in China.

The company has launched development plans through its new EV unit to create vehicles for the subcompact and mini compact categories. In the past few months, the growth of the EV market has become explosive. And in China, the demand for compact EVs is high and growing substantially. 

Estimates show that sales of subcompact and mini compact electric cars are currently projected to reach 5 million units by 2025 in the country. Since this announcement was made by Kaixin, the company’s stock price has increased by more than 77.8%. With this exciting news in mind, will you add KXIN to your penny stock watchlist this month?

Penny_Stocks_to_Watch_Kaixin_Auto_Holdings_KXIN_Stock_Chart

Are Penny Stocks Worth It?

At the end of the day, finding the best penny stocks to buy all comes down to what type of trader you are and your investing goals. These two factors alone will help you to narrow down your search substantially.

[Read More] Why The Stock Market Is Down Today & 3 Penny Stocks To Watch Now

And with so much going on in the market right now, it can be difficult to stay up to date. So, considering all of this, do you think that penny stocks are worth it or not?

The post 3 Penny Stocks To Buy For Under $4 On Robinhood Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Related Topics:
Continue Reading

International

Home buyers must now navigate higher mortgage rates and prices

Rates under 4% came and went during the Covid pandemic, but home prices soared. Here’s what buyers and sellers face as the housing season ramps up.

Published

5 hours ago

on

March 17, 2024

By

Springtime is spreading across the country. You can see it as daffodil, camellia, tulip and other blossoms start to emerge. 

You can also see it in the increasing number of for sale signs popping up in front of homes, along with the painting, gardening and general sprucing up as buyers get ready to sell. 

Which leads to two questions: 

  • How is the real estate market this spring? 
  • Where are mortgage rates? 

What buyers and sellers face

The housing market is bedeviled with supply shortages, high prices and slow sales.

Mortgage rates are still high and may limit what a buyer can offer and a seller can expect.  

Related: Analyst warns that a TikTok ban could lead to major trouble for Apple, Big Tech

And there's a factor not expected that may affect the sales process. Fixed commission rates on home sales are going away in July.

Reports this week and in a week will make the situation clearer for buyers and sellers. 

The reports are:

  • Housing starts from the U.S. Commerce Department due Tuesday. The consensus estimate is for a seasonally adjusted rate of about 1.4 million homes. These would include apartments, both rentals and condominiums. 
  • Existing home sales, due Thursday from the National Association of Realtors. The consensus estimate is for a seasonally adjusted sales rate of about 4 million homes. In 2023, some 4.1 million homes were sold, the worst sales rate since 1995. 
  • New-home sales and prices, due Monday from the Commerce Department. Analysts are expecting a sales rate of 661,000 homes (including condos), up 1.5% from a year ago.

Here is what buyers and sellers need to know about the situation. 

Mortgage rates will stay above 5% 

That's what most analysts believe. Right now, the rate on a 30-year mortgage is between 6.7% and 7%. 

Rates peaked at 8% in October after the Federal Reserve signaled it was done raising interest rates.

The Freddie Mac Primary Mortgage Market Survey of March 14 was at 6.74%. 

Freddie Mac buys mortgages from lenders and sells securities to investors. The effect is to replenish lenders' cash levels to make more loans. 

A hotter-than-expected Producer Price Index released that day has pushed quotes to 7% or higher, according to data from Mortgage News Daily, which tracks mortgage markets.

Home buyers must navigate higher mortgage rates and prices this spring.

TheStreet

On a median-priced home (price: $380,000) and a 20% down payment, that means a principal and interest rate payment of $2,022. The payment  does not include taxes and insurance.

Last fall when the 30-year rate hit 8%, the payment would have been $2,230. 

In 2021, the average rate was 2.96%, which translated into a payment of $1,275. 

Short of a depression, that's a rate that won't happen in most of our lifetimes. 

Most economists believe current rates will fall to around 6.3% by the end of the year, maybe lower, depending on how many times the Federal Reserve cuts rates this year. 

If 6%, the payment on our median-priced home is $1,823.

But under 5%, absent a nasty recession, fuhgettaboutit.

Supply will be tight, keeping prices up

Two factors are affecting the supply of homes for sale in just about every market.

First: Homeowners who had been able to land a mortgage at 2.96% are very reluctant to sell because they would then have to find a home they could afford with, probably, a higher-cost mortgage.

More economic news:

Second, the combination of high prices and high mortgage rates are freezing out thousands of potential buyers, especially those looking for homes in lower price ranges.

Indeed, The Wall Street Journal noted that online brokerage Redfin said only about 20% of homes for sale in February were affordable for the typical household.

And here mortgage rates can play one last nasty trick. If rates fall, that means a buyer can afford to pay more. Sellers and their real-estate agents know this too, and may ask for a higher price. 

Covid's last laugh: An inflation surge

Mortgage rates jumped to 8% or higher because since 2022 the Federal Reserve has been fighting to knock inflation down to 2% a year. Raising interest rates was the ammunition to battle rising prices.

In June 2022, the consumer price index was 9.1% higher than a year earlier. 

The causes of the worst inflation since the 1970s were: 

  • Covid-19 pandemic, which caused the global economy to shut down in 2020. When Covid ebbed and people got back to living their lives, getting global supply chains back to normal operation proved difficult. 
  • Oil prices jumped to record levels because of the recovery from the pandemic recovery and Russia's invasion of Ukraine.

What the changes in commissions means

The long-standing practice of paying real-estate agents will be retired this summer, after the National Association of Realtors settled a long and bitter legal fight.

No longer will the seller necessarily pay 6% of the sale price to split between buyer and seller agents.

Both sellers and buyers will have to negotiate separately the services agents have charged for 100 years or more. These include pre-screening properties, writing sales contracts, and the like. The change will continue a trend of adding costs and complications to the process of buying or selling a home.

Already, interest rates are a complication. In addition, homeowners insurance has become very pricey, especially in communities vulnerable to hurricanes, tornadoes, and forest fires. Florida homeowners have seen premiums jump more than 102% in the last three years. A policy now costs three times more than the national average.

Related: Veteran fund manager picks favorite stocks for 2024

 

Read More

Continue Reading

International

Mistakes Were Made

Mistakes Were Made

Authored by C.J.Hopkins via The Consent Factory,

Make fun of the Germans all you want, and I’ve certainly done that…

Published

1 day ago

on

March 17, 2024

By

Mistakes Were Made

Authored by C.J.Hopkins via The Consent Factory,

Make fun of the Germans all you want, and I’ve certainly done that a bit during these past few years, but, if there’s one thing they’re exceptionally good at, it’s taking responsibility for their mistakes. Seriously, when it comes to acknowledging one’s mistakes, and not rationalizing, or minimizing, or attempting to deny them, and any discomfort they may have allegedly caused, no one does it quite like the Germans.

Take this Covid mess, for example. Just last week, the German authorities confessed that they made a few minor mistakes during their management of the “Covid pandemic.” According to Karl Lauterbach, the Minister of Health, “we were sometimes too strict with the children and probably started easing the restrictions a little too late.” Horst Seehofer, the former Interior Minister, admitted that he would no longer agree to some of the Covid restrictions today, for example, nationwide nighttime curfews. “One must be very careful with calls for compulsory vaccination,” he added. Helge Braun, Head of the Chancellery and Minister for Special Affairs under Merkel, agreed that there had been “misjudgments,” for example, “overestimating the effectiveness of the vaccines.”

This display of the German authorities’ unwavering commitment to transparency and honesty, and the principle of personal honor that guides the German authorities in all their affairs, and that is deeply ingrained in the German character, was published in a piece called “The Divisive Virus” in Der Spiegel, and immediately widely disseminated by the rest of the German state and corporate media in a totally organic manner which did not in any way resemble one enormous Goebbelsian keyboard instrument pumping out official propaganda in perfect synchronization, or anything creepy and fascistic like that.

Germany, after all, is “an extremely democratic state,” with freedom of speech and the press and all that, not some kind of totalitarian country where the masses are inundated with official propaganda and critics of the government are dragged into criminal court and prosecuted on trumped-up “hate crime” charges.

OK, sure, in a non-democratic totalitarian system, such public “admissions of mistakes” — and the synchronized dissemination thereof by the media — would just be a part of the process of whitewashing the authorities’ fascistic behavior during some particularly totalitarian phase of transforming society into whatever totalitarian dystopia they were trying to transform it into (for example, a three-year-long “state of emergency,” which they declared to keep the masses terrorized and cooperative while they stripped them of their democratic rights, i.e., the ones they hadn’t already stripped them of, and conditioned them to mindlessly follow orders, and robotically repeat nonsensical official slogans, and vent their impotent hatred and fear at the new “Untermenschen” or “counter-revolutionaries”), but that is obviously not the case here.

No, this is definitely not the German authorities staging a public “accountability” spectacle in order to memory-hole what happened during 2020-2023 and enshrine the official narrative in history. There’s going to be a formal “Inquiry Commission” — conducted by the same German authorities that managed the “crisis” — which will get to the bottom of all the regrettable but completely understandable “mistakes” that were made in the heat of the heroic battle against The Divisive Virus!

OK, calm down, all you “conspiracy theorists,” “Covid deniers,” and “anti-vaxxers.” This isn’t going to be like the Nuremberg Trials. No one is going to get taken out and hanged. It’s about identifying and acknowledging mistakes, and learning from them, so that the authorities can manage everything better during the next “pandemic,” or “climate emergency,” or “terrorist attack,” or “insurrection,” or whatever.

For example, the Inquiry Commission will want to look into how the government accidentally declared a Nationwide State of Pandemic Emergency and revised the Infection Protection Act, suspending the German constitution and granting the government the power to rule by decree, on account of a respiratory virus that clearly posed no threat to society at large, and then unleashed police goon squads on the thousands of people who gathered outside the Reichstag to protest the revocation of their constitutional rights.

Once they do, I’m sure they’ll find that that “mistake” bears absolutely no resemblance to the Enabling Act of 1933, which suspended the German constitution and granted the government the power to rule by decree, after the Nazis declared a nationwide “state of emergency.”

Another thing the Commission will probably want to look into is how the German authorities accidentally banned any further demonstrations against their arbitrary decrees, and ordered the police to brutalize anyone participating in such “illegal demonstrations.”

And, while the Commission is inquiring into the possibly slightly inappropriate behavior of their law enforcement officials, they might want to also take a look at the behavior of their unofficial goon squads, like Antifa, which they accidentally encouraged to attack the “anti-vaxxers,” the “Covid deniers,” and anyone brandishing a copy of the German constitution.

Come to think of it, the Inquiry Commission might also want to look into how the German authorities, and the overwhelming majority of the state and corporate media, accidentally systematically fomented mass hatred of anyone who dared to question the government’s arbitrary and nonsensical decrees or who refused to submit to “vaccination,” and publicly demonized us as “Corona deniers,” “conspiracy theorists,” “anti-vaxxers,” “far-right anti-Semites,” etc., to the point where mainstream German celebrities like Sarah Bosetti were literally describing us as the inessential “appendix” in the body of the nation, quoting an infamous Nazi almost verbatim.

And then there’s the whole “vaccination” business. The Commission will certainly want to inquire into that. They will probably want to start their inquiry with Karl Lauterbach, and determine exactly how he accidentally lied to the public, over and over, and over again …

And whipped people up into a mass hysteria over “KILLER VARIANTS” …

And “LONG COVID BRAIN ATTACKS” …

And how “THE UNVACCINATED ARE HOLDING THE WHOLE COUNTRY HOSTAGE, SO WE NEED TO FORCIBLY VACCINATE EVERYONE!”

And so on. I could go on with this all day, but it will be much easier to just refer you, and the Commission, to this documentary film by Aya Velázquez. Non-German readers may want to skip to the second half, unless they’re interested in the German “Corona Expert Council” …

Look, the point is, everybody makes “mistakes,” especially during a “state of emergency,” or a war, or some other type of global “crisis.” At least we can always count on the Germans to step up and take responsibility for theirs, and not claim that they didn’t know what was happening, or that they were “just following orders,” or that “the science changed.”

Plus, all this Covid stuff is ancient history, and, as Olaf, an editor at Der Spiegel, reminds us, it’s time to put the “The Divisive Pandemic” behind us …

… and click heels, and heil the New Normal Democracy!

Tyler Durden Sat, 03/16/2024 - 23:20

Read More

Continue Reading

International

“Extreme Events”: US Cancer Deaths Spiked In 2021 And 2022 In “Large Excess Over Trend”

"Extreme Events": US Cancer Deaths Spiked In 2021 And 2022 In "Large Excess Over Trend"

Cancer deaths in the United States spiked in 2021…

Published

1 day ago

on

March 16, 2024

By

"Extreme Events": US Cancer Deaths Spiked In 2021 And 2022 In "Large Excess Over Trend"

Cancer deaths in the United States spiked in 2021 and 2022 among 15-44 year-olds "in large excess over trend," marking jumps of 5.6% and 7.9% respectively vs. a rise of 1.7% in 2020, according to a new preprint study from deep-dive research firm, Phinance Technologies.

Algeria, Carlos et. al "US -Death Trends for Neoplasms ICD codes: C00-D48, Ages 15-44", ResearchGate, March. 2024 P. 7

Extreme Events

The report, which relies on data from the CDC, paints a troubling picture.

"We show a rise in excess mortality from neoplasms reported as underlying cause of death, which started in 2020 (1.7%) and accelerated substantially in 2021 (5.6%) and 2022 (7.9%). The increase in excess mortality in both 2021 (Z-score of 11.8) and 2022 (Z-score of 16.5) are highly statistically significant (extreme events)," according to the authors.

That said, co-author, David Wiseman, PhD (who has 86 publications to his name), leaves the cause an open question - suggesting it could either be a "novel phenomenon," Covid-19, or the Covid-19 vaccine.

"The results indicate that from 2021 a novel phenomenon leading to increased neoplasm deaths appears to be present in individuals aged 15 to 44 in the US," reads the report.

The authors suggest that the cause may be the result of "an unexpected rise in the incidence of rapidly growing fatal cancers," and/or "a reduction in survival in existing cancer cases."

They also address the possibility that "access to utilization of cancer screening and treatment" may be a factor - the notion that pandemic-era lockdowns resulted in fewer visits to the doctor. Also noted is that "Cancers tend to be slowly-developing diseases with remarkably stable death rates and only small variations over time," which makes "any temporal association between a possible explanatory factor (such as COVID-19, the novel COVID-19 vaccines, or other factor(s)) difficult to establish."

That said, a ZeroHedge review of the CDC data reveals that it does not provide information on duration of illness prior to death - so while it's not mentioned in the preprint, it can't rule out so-called 'turbo cancers' - reportedly rapidly developing cancers, the existence of which has been largely anecdotal (and widely refuted by the usual suspects).

While the Phinance report is extremely careful not to draw conclusions, researcher "Ethical Skeptic" kicked the barn door open in a Thursday post on X - showing a strong correlation between "cancer incidence & mortality" coinciding with the rollout of the Covid mRNA vaccine.

Phinance principal Ed Dowd commented on the post, noting that "Cancer is suddenly an accelerating growth industry!"

Continued:

Bottom line - hard data is showing alarming trends, which the CDC and other agencies have a requirement to explore and answer truthfully - and people are asking #WhereIsTheCDC.

We aren't holding our breath.

Wiseman, meanwhile, points out that Pfizer and several other companies are making "significant investments in cancer drugs, post COVID."

Phinance

We've featured several of Phinance's self-funded deep dives into pandemic data that nobody else is doing. If you'd like to support them, click here.

 

Tyler Durden Sat, 03/16/2024 - 16:55

Read More

Continue Reading

Trending